TrialThe lancet. Diabetes & endocrinology2013

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

Mark R Rigby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.